Safety Issues in Iron Treatment in CKD

Seminars in Nephrology

Volumn 36, Issue 2, 2016, Pages 112-118

  Vaziri, Nosratola D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anemia; Cardiovascular disease; Infection; Inflammation; Neurologic disorders; Oxidative stress; Progression of kidney disease

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIETIN; FERRITIN; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 1; INTERLEUKIN 23; INTERLEUKIN 6; IRON; OXIDIZED LOW DENSITY LIPOPROTEIN; REACTIVE OXYGEN METABOLITE; TRANSFERRIN; TUMOR NECROSIS FACTOR ALPHA; FERRIC CITRATE; FERRIC ION; IRON DERIVATIVE;

ADAPTIVE IMMUNITY; ANEMIA; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CAROTID ARTERY DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHOLESTEROL DIET; CHRONIC KIDNEY DISEASE; COGNITION; COGNITIVE DEFECT; DEPRESSION; DIABETES MELLITUS; DIALYSIS; DISEASE ASSOCIATION; DRUG DOSAGE FORM COMPARISON; DRUG MEGADOSE; DRUG SAFETY; END STAGE RENAL DISEASE; FERRITIN BLOOD LEVEL; HEART FAILURE; HOSPITALIZATION; HUMAN; IMMUNE DEFICIENCY; IMMUNOPATHOGENESIS; INCIDENCE; INFECTION; INFECTION RISK; INFLAMMATION; INNATE IMMUNITY; IRON OVERLOAD; IRON THERAPY; LIVER DISEASE; MAINTENANCE THERAPY; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP DISORDER; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT WITHDRAWAL; UNITED STATES; VIRUS HEPATITIS; CHEMICALLY INDUCED; CHRONIC KIDNEY FAILURE; COMPLICATION; DISEASE EXACERBATION; HEMODIALYSIS; IRON DEFICIENCY ANEMIA; METABOLISM; OXIDATIVE STRESS;

ANEMIA, IRON-DEFICIENCY; CARDIOVASCULAR DISEASES; COGNITIVE DYSFUNCTION; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FERRIC COMPOUNDS; HEMATINICS; HUMANS; IRON COMPOUNDS; IRON OVERLOAD; KIDNEY FAILURE, CHRONIC; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84969579580     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2016.02.005     Document Type: Review

References (101)

1. Besarab A., Bolton W.K., Browne J.K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998, 339:584-590.
2. Drueke T.B., Locatelli F., Clyne N., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006, 355:2071-2084.
3. Singh A.K., Szczech L., Tang K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006, 355:2085-2098.
4. Szczech L.A., Barnhart H.X., Inrig J.K., et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008, 74:791-798.
5. Goodkin D.A., Fuller D.S., Robinson B.M., et al. Naturally occurring higher hemoglobin concentration does not increase mortality among hemodialysis patients. J Am Soc Nephrol 2011, 22:358-365.
6. Karaboyas A., Zee J., Morgenstern H., et al. Understanding the recent increase in ferritin levels in United States dialysis patients: potential impact of changes in intravenous iron and erythropoiesis-stimulating agent dosing. Clin J Am Soc Nephrol 2015, 10:1814-1821.
7. Himmelfarb J., Stenvinkel P., Ikizler T.A., Hakim R.M. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002, 62:1524-1538.
8. Stenvinkel P. Inflammation in end-stage renal disease: the hidden enemy. Nephrology (Carlton) 2006, 11:36-41.
9. Lim C.S., Vaziri N.D. The effects of iron dextran on the oxidative stress in cardiovascular tissues of rats with chronic renal failure. Kidney Int 2004, 65:1802-1809.
10. Vaziri N.D. Oxidative stress in uremia: nature, mechanisms, and potential consequences. Semin Nephrol 2004, 24:469-473.
11. Vaziri N.D. Anemia and anemia correction: surrogate markers or causes of morbidity in chronic kidney disease?. Nat Clin Pract Nephrol 2008, 4:436-445.
12. Vaziri N.D., Zhou X.J. Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease. Nephrol Dial Transplant 2009, 24:1082-1088.
13. Kamanna V.S., Ganji S.H., Shelkovnikov S., Norris K., Vaziri N.D. Iron sucrose promotes endothelial injury and dysfunction and monocyte adhesion/infiltration. Am J Nephrol 2011, 29:114-119.
14. Connor J.R., Zhang X., Nixon A.M., Webb B., Perno J.R. Comparative evaluation of nephrotoxicity and management by macrophages of intravenous pharmaceutical iron formulations. PLoS One 2015, 10:e0125272.
15. Zhou X.J., Laszik Z., Wang X.Q., Silva F.G., Vaziri N.D. Association of renal injury with increased oxygen free radical activity and altered nitric oxide metabolism in chronic experimental hemosiderosis. Lab Invest 2000, 80:1905-1914.
16. Van Campenhout A., Van Campenhout C., Lagrou A., Manuel-y-Keenoy B. Iron-induced oxidative stress in haemodialysis patients: a pilot study on the impact of diabetes. Biometals 2008, 21:159-170.
17. Kuo K.L., Hung S.C., Wei Y.H., Tarng D.C. Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients. J Am Soc Nephrol 2008, 19:1817-1826.
18. Garcia-Fernandez N., Echeverria A., Sanchez-Ibarrola A. Randomized clinical trial on acute effects of i.v. iron sucrose during haemodialysis. Nephrology 2010, 15:178-183.
19. Agarwal R., Kusek J.W., Pappas M.K. A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int 2015, 88:905-914.
20. Kuo K.L., Hung S.C., Lee T.S., Tarng D.C. Iron sucrose accelerates early atherogenesis by increasing superoxide production and upregulating adhesion molecules in CKD. J Am Soc Nephrol 2014, 25:2596-2606.
21. Carlini R., Alonzo E., Belloni-Font E., Weisinger J. Apoptotic stress pathway activation mediated by iron on endothelial cells in vitro. Nephrol Dial Transplant 2006, 21:3055-3061.
22. Rooyakkers T.M., Stroes E.S., Kooistra M.P., et al. Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest 2002, 32(Suppl 1):9-16.
23. Kielstein J.T., Boger R.H., Bode-Boger S.M., et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 1999, 10:594-600.
24. Zoccali C., Bode-Boger S., Mallamaci F., et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001, 358:2113-2117.
25. Drüeke T., Witko-Sarsat V., Massy Z., Descamps-Latscha B., Guerin A.P., Marchais S.J., et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002, 106:2212-2217.
26. Reis K.A., Guz G., Ozdemir H., et al. Intravenous iron therapy as a possible risk factor for atherosclerosis in end stage renal disease. Int Heart J 2005, 46:255-264.
27. Minqin R., Rajendran R., Pan N., et al. The iron chelator desferrioxamine inhibits atherosclerotic lesion development and decreases lesion iron concentrations in the cholesterol-fed rabbit. Free Radic Biol Med 2005, 38:1206-1211.
28. Minqin R., Watt F., Huat B.T., Halliwell B. Correlation of iron and zinc levels with lesion depth in newly formed atherosclerotic lesions. Free Radic Biol Med 2003, 34:746-752.
29. Sawada H., Hao H., Naito Y., et al. Aortic iron overload with oxidative stress and inflammation in human and murine abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 2015, 35:1507-1514.
30. Stadler N., Lindner R.A., Davies M.J. Direct detection and quantification of transition metal ions in human atherosclerotic plaques: evidence for the presence of elevated levels of iron and copper. Arterioscler Thromb Vasc Biol 2004, 24:949-954.
31. Li W., Hellsten A., Xu L.H., et al. Foam cell death induced by 7beta-hydroxycholesterol is mediated by labile iron-driven oxidative injury: mechanisms underlying induction of ferritin in human atheroma. Free Radic Biol Med 2005, 39:864-875.
32. Li W., Ostblom M., Xu L.H., et al. Cytocidal effects of atheromatous plaque components: the death zone revisited. FASEB J 2006, 20:2281-2290.
33. Porreca E., Ucchino S., Di Febbo C., et al. Antiproliferative effect of desferrioxamine on vascular smooth muscle cells in vitro and in vivo. Arterioscler Thromb 1994, 14:299-304.
34. Neven E., De Schutter T.M., Behets G.J., Gupta A., D'Haese P.C. Iron and vascular calcification. Is there a link? Nephrol Dial Transplant 2011, 26:1137-1145.
35. Vaziri N.D., Pahl M.V., Crum A., Norris K. Effect of uremia on function and structure of immune system. J Ren Nutr 2012, 22:149-156.
36. Vaziri N.D., Navab M., Fogelman A.M. HDL metabolism and activity in chronic kidney disease. Nat Rev Nephrol 2010, 6:287-296.
37. Vaziri N.D., Norris K. Lipid disorders and their relevance to outcomes in chronic kidney disease. Blood Purif 2011, 31:189-196.
38. Vaziri N.D., Zhao Y.Y., Pahl M.V. Altered intestinal microbial flora and impaired epithelial barrier structure and function in CKD: the nature, mechanisms, consequences and potential treatment. Nephrol Dial Transplant 2015, [Epub ahead of print].
39. Yoon J.W., Pahl M.V., Vaziri N.D. Spontaneous leukocyte activation and oxygen-free radical generation in end-stage renal disease. Kidney Int 2007, 71:167-172.
40. Gollapudi P., Yoon J.W., Gollapudi S., Pahl M.V., Vaziri N.D. Leukocyte toll-like receptor expression in end-stage kidney disease. Am J Nephrol 2010, 31:247-254.
41. Meier P., Golshayan D., Blanc E., Pascual M., Burnier M. Oxidized LDL modulates apoptosis of regulatory T cells in patients with ESRD. J Am Soc Nephrol 2009, 20:1368-1384.
42. Vaziri N.D. Roles of oxidative stress and antioxidant therapy in chronic renal disease and hypertension. Curr Opin Nephrol Hypertens 2004, 13:93-99.
43. Agrawal S., Gollapudi P., Elahimehr R., Pahl M.V., Vaziri N.D. Effects of end-stage renal disease and haemodialysis on dendritic cell subsets and basal and LPS-stimulated cytokine production. Nephrol Dial Transplant 2010, 25:737-746.
44. Yoon J., Gollapudi S., Pahl M., Vaziri N. Naive and central memory T-cell lymphopenia in end-stage renal disease. Kidney Int 2006, 70:371-376.
45. Pahl M.V., Gollapudi S., Sepassi L., Gollapudi P., Elahimehr R., Vaziri N.D. Effect of end-stage renal disease on B-lymphocyte subpopulations, IL-7, BAFF and BAFF receptor expression. Nephrol Dial Transplant 2010, 25:205-212.
46. Smogorzewski M., Massry S.G. Defects in B-cell function and metabolism in uremia: role of parathyroid hormone. Kidney Int 2001, 78:S186-S189.
47. Liakopoulos V., Markala D. Decreased CD3+CD16+ natural killer-like T-cell percentage and zeta-chain expression accompany chronic inflammation in hemodialysis patients. Nephrology 2009, 14:471-475.
48. Vacher-Coponat H., Brunet C., Lyonnet L., Bonnet E., Loundou A., Sampol J., et al. Natural killer cell alterations correlate with loss of renal function and dialysis duration in hemodialysis patients. Nephrol Dial Transplant 2008, 23:1406-1414.
49. Alexiewicz J.M., Smogorzewski M., Fadda G.Z., Massry S.G. Impaired phagocytosis in dialysis patients: studies on mechanisms. Am J Nephrol 1991, 11:102-111.
50. Massry S., Smogorzewski M. Dysfunction of polymorphonuclear leukocytes in uremia: role of parathyroid hormone. Kidney Int 2001, 78:S195-S196.
51. Kuvibidila S.R., Porretta C., Surendra Baliga B., Leiva L.E. Reduced thymocyte proliferation but not increased apoptosis as a possible cause of thymus atrophy in iron-deficient mice. Br J Nutr 2001, 86:157-162.
52. Farmakis D., Giakoumis A., Polymeropoulos E., Aessopos A. Pathogenetic aspects of immune deficiency associated with betathalassemia. Med Sci Monit 2003, 9:RA19-RA22.
53. Porto G., De Sousa M. Iron overload and immunity. World J Gastroenterol 2007, 13:4707-4715.
54. Djeha A., Brock J.H. Uptake and intracellular handling of iron from transferrin and iron chelates by mitogen stimulated mouse lymphocytes. Biochem Biophys Acta 1992, 1133:147-152.
55. Gupta A., Zhuo J., Zha J., Reddy S., Olp J., Pai A. Effect of different intravenous iron preparations on lymphocyte intracellular reactive oxygen species generation and subpopulation survival. BMC Nephrol 2010, 11:16.
56. Deicher R., Ziai F., Cohen G., Müllner M., Hörl W.H. High dose parenteral iron sucrose depresses neutrophil intracellular killing capacity. Kidney Int 2003, 64:728-736.
57. Patruta S.I., Edlinger R., Sunder-Plassmann G., Hörl W.H. Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 1998, 9:655-663.
58. van Asbeck B.S., Marx J.J., Struyvenberg A., Verhoef J. Functional defects in phagocytic cells from patients with iron overload. J Infect 1984, 8:232-240.
59. Waterlot Y., Cantinieaux B., Hariga-Muller C., et al. Impaired phagocytic activity of neutrophils in patients receiving haemodialysis: The critical role of iron overload. Br Med J (Clin Res Ed) 1985, 291:501-504.
60. Liu J.H., Liu Y.L., Lin H.H., Yang Y.F., Kuo H.L., Lin P.W., et al. Intravenous iron attenuates postvaccination anti-HBsAg titers after quadruple hepatitis B vaccination in dialysis patients with erythropoietin therapy. Int J Clin Pract 2009, 63:387-393.
61. Bonkovsky H.L., Banner B.F., Lambrecht R.W., Rubin R.B. Iron in liver diseases other than hemochromatosis. Semin Liver Dis 1996, 16:65-82.
62. Shan Y., Lambrecht R.W., Bonkovsky H.L. Association of hepatitis C virus infection with serum iron status: analysis of data from the third National Health and Nutrition Examination Survey. Clin Infect Dis 2005, 40:834-841.
63. Porcheron G., Dozois C.M. Interplay between iron homeostasis and virulence: Fur and RyhB as major regulators of bacterial pathogenicity. Vet Microbiol 2015, 179:2-14.
64. Brookhart M.A., Freburger J.K., Ellis A.R., Wang L., Winkelmayer W.C., Kshirsagar A.V. Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Soc Nephrol 2013, 24:1151-1158.
65. Pai A.B., Conner T., McQuade C.R., Olp J., Hicks P. Non-transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving intravenous iron dextran or iron sucrose. Biometals 2011, 24:603-613.
66. Sindrilaru A., Peters T., Wieschalka S., Baican C., Baican A., Peter H., et al. An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice. J Clin Invest 2011, 121:985-997.
67. Mosser D.M., Edwards J.P. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008, 8:958-996.
68. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003, 3:23-35.
69. Dale D.C., Boxer L., Liles W.C. The phagocytes: neutrophils and monocytes. Blood 2008, 112:935-945.
70. Angelucci E., Brittenham G.M., McLaren C.E., et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 2000, 343:327-331.
71. Canavese C., Bergamo D., Ciccone G., et al. Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int 2004, 65:1091-1098.
72. Ferrari P., Kulkarni H., Dheda S., et al. Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. Clin J Am Soc Nephrol 2011, 6:77-83.
73. Rostoker G., Griuncelli M., Loridon C., et al. Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study. Am J Med 2012, 125. 991-9 e991.
74. Brissot P., Troadec M.B., Bardou-Jacquet E., et al. Current approach to hemochromatosis. Blood Rev 2008, 22:195-210.
75. Desai T.K., Jamil L.H., Balasubramaniam M., Koff R., Bonkovsky H.L. Phlebotomy improves therapeutic response to interferon in patients with chronic hepatitis C: a meta-analysis of six prospective randomized controlled trials. Dig Dis Sci 2008, 53:815-822.
76. Lambrecht R.W., Sterling R.K., Naishadham D., et al. Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C. Gastroenterology 2011, 140. 1490-500 e1493.
77. Swaminathan S., Fonseca V.A., Alam M.G., Shah S.V. The role of iron in diabetes and its complications. Diabetes Care 2007, 30:1926-1933.
78. Tiedge M., Lortz S., Drinkgern J., Lenzen S. Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells. Diabetes 1997, 46:1733-1742.
79. Andrews N.C. The iron transporter DMT1. Int J Biochem Cell Biol 1999, 31:991-994.
80. Sheu W.H., Chen Y.T., Lee W.J., Wang C.W., Lin L.Y. A relationship between serum ferritin and the insulin resistance syndrome is present in non-diabetic women but not in non-diabetic men. Clin Endocrinol (Oxf) 2003, 58:380-385.
81. Rajpathak S., Ma J., Manson J., Willett W.C., Hu F.B. Iron intake and the risk of type 2 diabetes in women: a prospective cohort study. Diabetes Care 2006, 29:1370-1376.
82. Jehn M., Clark J.M., Guallar E. Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care 2004, 27:2422-2428.
83. Bozzini C., Girelli D., Olivieri O., et al. Prevalence of body iron excess in the metabolic syndrome. Diabetes Care 2005, 28:2061-2063.
84. Chen X., Scholl T.O., Stein T.P. Association of elevated serum ferritin levels and the risk of gestational diabetes mellitus in pregnant women: the Camden study. Diabetes Care 2006, 29:1077-1082.
85. Fernandez-Real J.M., Penarroja G., Castro A., Garcia-Bragado F., Hernandez-Aguado I., Ricart W. Blood letting in high-ferritin type 2 diabetes: effects on insulin sensitivity and beta-cell function. Diabetes 2002, 51:1000-1004.
86. Bofill C., Joven J., Bages J., et al. Response to repeated phlebotomies in patients with non-insulin-dependent diabetes mellitus. Metabolism 1994, 43:614-620.
87. Lao T.T., Ho L.F. Impact of iron deficiency anemia on prevalence of gestational diabetes mellitus. Diabetes Care 2004, 27:650-656.
88. Qian M., Liu M., Eaton J.W. Transition metals bind to glycated proteins forming redox active "glycochelates": implications for the pathogenesis of certain diabetic complications. Biochem Biophys Res Commun 1998, 250:385-389.
89. Young I.S., Tate S., Lightbody J.H., McMaster D., Trimble E.R. The effects of desferrioxamine and ascorbate on oxidative stress in the streptozotocin diabetic rat. Free Radic Biol Med 1995, 18:833-840.
90. Ha H., Kim K.H. Role of oxidative stress in the development of diabetic nephropathy. Kidney Int Suppl 1995, 51:S18-S21.
91. Shah S.V., Baliga R., Rajapurkar M., Fonseca V.A. Oxidants in chronic kidney disease. J Am Soc Nephrol 2007, 18:16-28.
92. Rajapurkar M.M., Hegde U., Bhattacharya A., Alam M.G., Shah S.V. Effect of deferiprone, an oral iron chelator, in diabetic and non-diabetic glomerular disease. Toxicol Mech Methods 2013, 23:5-10.
93. Kurella Tamura M., Yaffe K. Dementia and cognitive impairment in ESRD: diagnostic and therapeutic strategies. Kidney Int 2011, 79:14-22.
94. Whitmer R.A., Sidney S., Selby J., Johnston S.C., Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005, 64:277-281.
95. Kivipelto M., Helkala E.L., Hanninen T., et al. Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study. Neurology 2001, 56:1683-1689.
96. Knopman D., Boland L.L., Mosley T., et al. Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology 2001, 56:42-48.
97. Kell D.B. Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples. Arch Toxicol 2010, 84:825-889.
98. Deng G., Vaziri N.D., Jabbari B., Ni Z., Yan X.X. Increased tyrosine nitration of the brain in chronic renal insufficiency: reversal by antioxidant therapy and angiotensin-converting enzyme inhibition. J Am Soc Nephrol 2001, 12:1892-1899.
99. Singh N.P., Sahni V., Wadhwa A., et al. Effect of improvement in anemia on electroneurophysiological markers (P300) of cognitive dysfunction in chronic kidney disease. Hemodial Int 2006, 10:267-273.
100. Pickett J.L., Theberge D.C., Brown W.S., Schweitzer S.U., Nissenson A.R. Normalizing hematocrit in dialysis patients improves brain function. Am J Kidney Dis 1999, 33:1122-1130.
101. Tsubakihara Y., Nishi S., Akiba T., et al. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Ther Apher Dial 2010, 14:240-275.